Image theory, perception and processing course
Course dates
February 2026 Dates TBC
Venue
The Royal Marsden Education and Conference Centre, Stewart’s Grove, London SW3 6JJ.
Course overview
The course is organised by the Joint Department of Physics of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research.
This is a one-day course which covers the underpinning mathematics of medical imaging, comprising image formation, image processing techniques, human visual perception and image display techniques including three-dimensional methods. The material in this course is generally applicable to all types of imaging systems. Illustrations and examples from medical imaging will be used throughout including ultrasound, nuclear medicine, MRI, and x-ray CT.
The course is aimed at individuals who are undertaking formal training in medical physics. As well as being suitable for new entrants to the medical physics profession, it would also be of benefit to post-graduate students, post-doctoral research workers, representatives of allied commercial organisations and anyone wishing to deepen or re-establish their understanding of the mathematical techniques underpinning medical image formation, display and processing.
This is a CPD course approved by IPEM.
Provisional lecture list
- Mathematics of image formation
- Image processing techniques
- Perception and interpretation of medical images
- Three-dimensional image display
- Demonstration of image processing techniques
Registration & Course fees
All current course registration fees are given on our registration form.
The cost includes lunches and light refreshments. Electronic copies of the presentations and a certificate of attendance are provided.
You will be allocated a place on receipt of a completed registration form and a valid quoted payment reference/purchase order or completed bank transfer. We are unable to accept provisional bookings.
The number of participants is limited, so early booking is advised. Applications from outside the UK are welcome.
Closing date for registrations – Friday 24 January 2025
Related documents
Contacts
Course Organiser: Dr Jamie Dormand
For registration details and any other queries contact:
Course Administrator: Mrs Jessica Keegan
Latest ICR News
Silencing gene may combat formation of radiation-induced scar tissue, a new study reveals
A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.
_kevin-harrington-embed.jpg?sfvrsn=cb25ea76_1 "t-vec-infected-melanoma-cells-(green)_kevin-harrington-embed")
ASCO 2025: One-time cell therapy offers long-term survival hope for patients with advanced melanoma
A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.
ASCO 2025: Next-generation breast cancer drug targets tumours before they have a chance to grow
A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy.
Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.
.jpg?sfvrsn=5e059cab_3 "turnerasco2 (1)")
ASCO 2025: New therapy improves survival in advanced breast cancer and delays need for chemotherapy
A promising new therapy can help patients with aggressive advanced breast cancer live longer and delays the need for further chemotherapy, new research has shown.
Final results of the INAVO120 study, led by an international team of researchers including scientists at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, have demonstrated the potential of the new therapy combination for targeting PIK3CA-mutated hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer – a common form of the disease.